ZYN's FDA reduced-risk claim, explained: which 20 pouches have it and what it actually says
In June 2026 the FDA let 20 ZYN nicotine pouch products carry a modified-risk claim — a first for the category. Here's the exact wording, the full product list, and why it matters for every pouch brand.
Evergreen explainer — first published July 2026. The FDA decision itself came on June 30, 2026.
On June 30, 2026, the FDA did something it had never done for a nicotine pouch: it issued modified risk granted orders to Swedish Match USA for 20 ZYN products. Those products can now legally be marketed with a reduced-risk claim — the first time any nicotine pouch has been allowed to say anything like that in the US.
The exact claim
The FDA didn't approve vague messaging. The authorized wording is specific:
"Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis."
That sentence can only be used for the 20 products on the granted-order list — not for ZYN as a brand, and not for any other pouch.
Which products got it
Each flavor below was authorized in two nicotine strengths, 3 mg and 6 mg — ten flavors, twenty products:
- ZYN Chill
- ZYN Cinnamon
- ZYN Citrus
- ZYN Coffee
- ZYN Cool Mint
- ZYN Menthol
- ZYN Peppermint
- ZYN Smooth
- ZYN Spearmint
- ZYN Wintergreen
All 20 had already been authorized for sale through the premarket (PMTA) pathway since January 2025. The modified-risk order is a separate, optional step — and a much rarer one.
How the FDA reached the decision
A modified risk order requires the manufacturer to show three things: that the claim is scientifically accurate for the specific product, that consumers actually understand it, and that marketing it would benefit the population as a whole. FDA's review leaned on the January 22, 2026 meeting of its Tobacco Products Scientific Advisory Committee, public comments, and Swedish Match's application data — covering relative health risks, consumer perception, youth risk and population impact.
"The FDA's review of modified risk products is intended to ensure that adult users have clear, science-based information about the relative harms of tobacco products, so they can make informed choices," said Bret Koplow, acting director of FDA's Center for Tobacco Products, in the announcement.
Why it matters beyond ZYN
An FDA-endorsed reduced-risk claim is a marketing weapon no cigarette or other pouch brand holds. Rivals can't copy the wording without their own granted orders — which means years of applications and review. Expect other manufacturers with FDA-authorized pouches to file their own modified-risk applications, and expect the claim to show up in ZYN advertising, retail displays and comparison messaging.
For adult consumers, it's the first time the US regulator has formally put in writing that switching from cigarettes to a specific nicotine pouch lowers the risk of six named diseases. That's a real regulatory milestone, whatever one thinks of the politics around nicotine.
SOURCES
- FDA, CTP Newsroom: FDA Authorizes 20 ZYN Nicotine Pouches to Be Marketed with Specific Modified Risk Claim (June 30, 2026)
- FDA: Modified Risk Granted Orders
- FDA: Swedish Match USA MRTP Applications for ZYN Products
Compare ZYN prices and strengths across retailers at PouchFinder.